Antonio Gaetano Pagana

Dr. Antonio Gaetano Pagana


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
FSFabio Stagno
Fabio Stagno
GMGiuseppe Mirabile
Giuseppe Mirabile
PRPatricia Rizzotti
Patricia Rizzotti
ABAdele Bottaro
Adele Bottaro
APAntonio Gaetano Pagana
Antonio Gaetano Pagana
AAAlessandro Allegra
Alessandro Allegra
Myelodysplastic syndromes represent a group of hematological neoplastic diseases caused by defective stem cells causing cytopenia and abnormal hematopoiesis. More than 30% of myelodysplastic syndrome cases develop into acute myeloid leukemia. An analysis of bone marrow samples, peripheral blood smears, multiparametric flow cytometry data, and clinical patient information is part of the current, time-consuming, and labor-intensive work up for myelodysplastic syndromes. Nowadays, clinical biomedical research has been transformed by the advent of artificial intelligence, specifically machine learning. Artificial intelligence (AI) can improve risk assessment and diagnosis, as well as boost the precision of clinical outcome prediction and illness classification. Algorithms based on artificial intelligence may be potentially helpful in discovering new needs for myelodysplastic syndrome-affected patients, choosing treatment and assessing minimal residual disease. In this review, we seek to identify the primary mechanisms and uses of artificial intelligence in myelodysplastic syndrome, pointing out its advantages and disadvantages while discussing the possible benefits of using AI pipelines in a therapeutic setting.

Verified
Journal Article
Open access
PDF file
LGLaura Giordano
Laura Giordano
APAntonio Gaetano Pagana
Antonio Gaetano Pagana
PMPaola Lucia Minciullo
Paola Lucia Minciullo
Manlio FazioManlio Fazio
Manlio Fazio
FSFabio Stagno
Fabio Stagno
AAAlessandro Allegra
Alessandro Allegra
Hemophilia, an X-linked bleeding disorder, is characterized by a deficiency in coagulation factors. It manifests as spontaneous bleeding, leading to severe complications if not properly managed. In contrast, acquired hemophilia is an autoimmune condition marked by the development of inhibitory antibodies against coagulation factors. Both forms present significant diagnostic and therapeutic challenges, highlighting the need for advanced genetic, molecular, laboratory, and clinical assessments. Recent advances in artificial intelligence have opened new avenues for the management of hemophilia. Machine learning and deep learning technologies enhance the ability to predict bleeding risks, optimize treatment regimens, and monitor disease progression with greater precision. Artificial intelligence-driven applications in medical imaging have also improved the detection of joint damage and hemarthrosis, ensuring timely interventions and better clinical outcomes. Moreover, the integration of artificial intelligence into clinical practice holds the potential to transform hemophilia care through predictive analytics and personalized medicine, promising not only faster and more accurate diagnoses but also a reduction in long-term complications. However, ethical considerations and the need for data standardization remain critical for its widespread adoption. The application of artificial intelligence in hemophilia represents a paradigm shift towards precision medicine, with the promise of significantly improving patient outcomes and quality of life.